
|Articles|January 11, 2022
- Pharmaceutical Executive-01-01-2022
- Volume 42
- Issue 1
Our View on 2022: Pharm Exec’s Annual Industry Outlook
Supply chain issues, psychedelic medicines, immunotherapies, social engagement, telemedicine, access barriers, corporate branding, and the rise of Chinese biotech are industry topics that deserve a closer look as we head into the future.
Advertisement
Follow the links below to read about each trend:
Articles in this issue
over 4 years ago
Keeping Tabs on Quality: The Rise of Digitalover 4 years ago
China Invests in Building Biotechover 4 years ago
Branding Takes on a New Lookover 4 years ago
Addressing Access Burdensover 4 years ago
Meeting the Patient—Virtuallyover 4 years ago
The Age of Influenceover 4 years ago
Boosting Immunotherapiesover 4 years ago
Pharma’s Psychedelic Experienceover 4 years ago
Supply Chain Procurementover 4 years ago
Breaking New Ground in BiopharmaAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
Pharmaceutical Executive Daily: FDA Approves Datroway
5




